Hartman Institute for Therapeutic Organ Regeneration

A new study reported that SARS-CoV-2, the virus that causes COVID, can infect dopamine neurons in the brain and trigger senescence—when a cell loses the ability to grow and divide.

A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer treatments, according to a new study from researchers at Weill Cornell Medicine.

A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in type 2 diabetes, according to a new study by Weill Cornell Medicine investigators.

In experiments of unprecedented scale, investigators at Weill Cornell Medicine and the National Institutes of Health have revealed new aspects of the complex genetics behind Type 2 diabetes.

Six teams pitched their innovations at the 2023 Biomedical Business Plan Challenge Final Pitch Day competition for $100,000 in prize money, which can be used to help build their company, with the goal of ushering in the next generation of life science innovation and patient care.

Stem cells from the human stomach can be converted into cells that secrete insulin in response to rising blood sugar levels, offering a promising approach to treating diabetes.

Endothelial cells—the cells that line blood vessels—grown alongside leukemia cells become corrupted and rescue the cancer cells from many chemotherapy drugs, a study by Weill Cornell Medicine investigators found.

Two genes working in concert sustain the integrity of healthy blood vessels, Weill Cornell Medicine investigators discovered in new research. 

With a generous gift of $10 million from Board of Fellows member Alan Hartman and his wife, Kim, Weill Cornell Medicine will establish a multidisciplinary research institute to advance organ regeneration and repair.